EHA 2011 - European Hematology Association - June 2011
Chronic Myeloid Leukemia - CML
List of abstracts by subject Search Abstract
Chronic myeloid leukemia – Biology – 10 June 2011
Chronic myeloid leukemia – Biology – 11 June 2011
Chronic myeloid leukemia - Clinical 1 - 10 June 2011
Chronic myeloid leukemia - Clinical 1 – 11 June 2011
Chronic myeloid leukemia - Biology & clinical 1 – 11 June 2011
Chronic myeloid leukemia - Clinical 2 – 11 June 2011
Chronic myeloid leukemia - Clinical 2 – 12 June 2011
Stem cell transplantation - Clinical 1 – 11 June 2011
Stem cell transplantation - Experimental & clinical - 10 June 2011
Experimental stem cell transplantation - 11 June 2011
Stem cell transplantation - Clinical 1 – 11 June 2011
Stem cell transplantation - Clinical 2 – 11 June 2011
Stem cell transplantation - Clinical 2 – 12 June 2011
Stem cell transplantation - Clinical 3 – 12 June 2011
Hematopoiesis, stem cells and microenvironment – 12 June 2011
Chronic myeloid leukemia – Biology – 10 June 2011
Chronic myeloid leukemia – Biology – 11 June 2011
Chronic myeloid leukemia - Clinical 1 - 10 June 2011
Chronic myeloid leukemia - Clinical 1 – 11 June 2011
Chronic myeloid leukemia - Biology & clinical 1 – 11 June 2011
Chronic myeloid leukemia - Clinical 2 – 11 June 2011
Chronic myeloid leukemia - Clinical 2 – 12 June 2011
Stem cell transplantation - Clinical 1 – 11 June 2011
Stem cell transplantation - Experimental & clinical - 10 June 2011
Experimental stem cell transplantation - 11 June 2011
Stem cell transplantation - Clinical 1 – 11 June 2011
Stem cell transplantation - Clinical 2 – 11 June 2011
Stem cell transplantation - Clinical 2 – 12 June 2011
Stem cell transplantation - Clinical 3 – 12 June 2011
Hematopoiesis, stem cells and microenvironment – 12 June 2011
Some interesting abstracts for CML
LOSS OF MAJOR MOLECULAR RESPONSE (MMR) IS MORE ACCURATE THAN LOSS OF COMPLETE MOLECULAR RESPONSE (CMR) FOR RESTARTING IMATINIB AFTER IMATINIB DISCONTINUATION IN CP-CML PATIENTS WITH LONG LASTING CMR
SECOND ATTEMPT OF IMATINIB DISCONTINUATION IN CP-CML PATIENTS WITH A SUSTAINED SECOND COMPLETE MOLECULAR REMISSION
CESSATION OF DASATINIB OR NILOTINIB THERAPY IN CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA PATIENTS WITH SUSTAINED COMPLETE MOLECULAR RESPONSES
CML PATIENTS TREATED WITH TKI’S WHO OBTAIN MAJOR MOLECULAR RESPONSE ARE HIGHLY PROTECTED FOR TRANSFORMATION AND THIS PROTECTION SEEMS TO BE INDEPENDENT OF THE 18-MONTH CUTOFF
TREATMENT OF CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO HARBOR THE BCR-ABL T315I MUTATION WITH SUBCUTANEOUS OMACETAXINE RESULTS IN IMPROVED SURVIVAL COMPARED TO HISTORICAL DATA
LOSS OF MAJOR MOLECULAR RESPONSE (MMR) IS MORE ACCURATE THAN LOSS OF COMPLETE MOLECULAR RESPONSE (CMR) FOR RESTARTING IMATINIB AFTER IMATINIB DISCONTINUATION IN CP-CML PATIENTS WITH LONG LASTING CMR
SECOND ATTEMPT OF IMATINIB DISCONTINUATION IN CP-CML PATIENTS WITH A SUSTAINED SECOND COMPLETE MOLECULAR REMISSION
CESSATION OF DASATINIB OR NILOTINIB THERAPY IN CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA PATIENTS WITH SUSTAINED COMPLETE MOLECULAR RESPONSES
CML PATIENTS TREATED WITH TKI’S WHO OBTAIN MAJOR MOLECULAR RESPONSE ARE HIGHLY PROTECTED FOR TRANSFORMATION AND THIS PROTECTION SEEMS TO BE INDEPENDENT OF THE 18-MONTH CUTOFF
TREATMENT OF CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO HARBOR THE BCR-ABL T315I MUTATION WITH SUBCUTANEOUS OMACETAXINE RESULTS IN IMPROVED SURVIVAL COMPARED TO HISTORICAL DATA
